A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

The European Commission (EC) has approved Novartis's Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in mediating the incapacitating pain of migraine. In the extensive clinical program of 2,600 patients, those on Aimovig experienced significant reductions in their number of migraine days per month, with a safety and tolerability profile similar to placebo. Aimovig can be self-administered or administered by another trained person every 4 weeks with the SureClick autoinjector pen, an established device commonly used for a range of different conditions.

A new era for migraine patients

"Migraine matters. It is a painful, highly disruptive neurological disease that affects all aspects of life, from going to work to spending time with family and friends," said Patrick Little, President of the European Migraine and Headache Alliance. "A treatment specifically designed for migraine prevention is a much-welcomed innovation and could transform lives of patients for whom current therapies do not work or are not well tolerated."

Aimovig showed efficacy even in a difficult-to-treat population. It is the only CGRP-R pathway therapy specifically studied in patients who had failed on two to four previous treatments commonly used for migraine prevention. Furthermore, in an interim analysis from a 5-year open-label extension (OLE) in episodic migraine, it was demonstrated that 26% of patients taking Aimovig 70 mg, who were still enrolled and assessed for migraine over month fifteen, were completely migraine free.

"Erenumab heralds a new era in clinical practice, bringing both a targeted mechanism for prevention and a deep understanding of migraine, which we have never had before," said Peter Goadsby, Director, NIHR-Wellcome Trust King's Clinical Research Facility and Professor of Neurology at King's College London. "We will see sustained relief from migraine for many of those who suffer with this debilitating disease."

"This approval is groundbreaking for people living with migraine, their families and doctors," said Paul Hudson, CEO Novartis Pharmaceuticals. "In clinical trials, Aimovig has consistently shown to be effective in preventing migraine and bringing relief from the grip of this disease. We are proud to be the first to reimagine migraine prevention and we are committed to ensuring Aimovig's availability for those who could benefit from it. We are launching a tailored post-approval access program and are exploring a number of innovative reimbursement and access approaches, including paying only for patients who respond well to treatment."

A post-approval access program has been opened to provide Aimovig in countries where the local regulations allow provision of unapproved or yet to be reimbursed therapies. Support programs are also being developed for eligible patients in line with local regulations that include personalized services, information and resources to support them as they begin their treatment with Aimovig.

The EMA decision is applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein. Aimovig (erenumab-aooe) received FDA approval for the preventive treatment of migraine in adults on 17 May 2018. Aimovig received Swissmedic approval in Switzerland on 13 July 2018 and Australian TGA registration on 3 July 2018. Additional regulatory filings are underway with other health authorities worldwide.

Read More

Related news

New formulation modelling successes using ex vivo tissue

New formulation modelling successes using ex vivo tissue

9 Oct 2018

One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New oral treatment for metastatic melanoma receives EU authorisation

New oral treatment for metastatic melanoma receives EU authorisation

24 Sep 2018

Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more